The case for & against
Bull & Bear analysis
Bearish
Sensus Healthcare, Inc. (NASDAQ:SRTS) is a leading provider of non-invasive treatments for skin cancer through its proprietary Superficial Radiotherapy (SRT) technology. The company operates within the healthcare sector and is currently exploring significant growth opportunities following recent regulatory changes. These changes include the implementation of dedicated CPT codes aimed at improving reimbursement clarity and adoption rates for SRT procedures. Sensus Healthcare is strategically positioned to leverage market demand for non-surgical treatment options amid growing awareness and preference for innovative dermatological therapies.
Bull says
- ↑Reimbursement rates surged ~300% post CPT codes, boosting revenue potential.
- ↑Q1 treatment volumes rose 8% YoY, reflecting rising market adoption.
- ↑Q1 cash $18.3m with zero debt supports growth initiatives.
- ↑Shipments to multiple new accounts reduce customer concentration risk.
- ↑Census Link software and education efforts aim to drive recurring revenues.
- ↑Strong qualitative factor metrics and low leverage risk support stability.
Bear says
- ↓Q1 2026 revenue fell to $3.4m from $8.3m YoY amid key customer loss.
- ↓Net loss $2.6m on $5.3m operating expenses raises profitability concerns.
- ↓Negative earnings yield and EPS revision risk weigh on valuation.
- ↓Persistent reliance on largest customer limits revenue predictability.
- ↓Uncertainty remains if new CPT codes will sustain long-term adoption.
- ↓Analyst caution implied from negative size and revision factor signals.
Earnings Call · Q1 2025 · Mgmt. Guidance
Updated 06-03-2026bullish
Transcript signals
Bull points
- We expect Q2 revenue to be higher than Q1 revenue, and we also expect that revenue in the second half of the year will be higher than the first half of the year.
- Our balance sheet remains strong as we ended the quarter with 19.1 million in cash, no debt, an inventory maintained at $9.9 million. This inventory level positions us to meet the anticipated demand in upcoming quarters for both direct and for placement under Deferred Deal Agreement.
- we believe we can sign three to five more of those type of groups by the end of the year, because those negotiations are ongoing.
Bear points
- Revenue for the first quarter of 2025 was 8.3 million, which was down from 10.7 million in Q1 of 2024, primarily due to lower unit sales to our largest customer.
- We reported a net loss for the first quarter of 2025 of 2.6 million, or a loss of 16 cents per share, compared to net income of 2.3 or 14 cents per diluted share in the prior year quarter.
- Adjusted EBITDA was negative 2.5 million for Q1 of 2025 compared with a positive 3 million a year ago, reflecting higher operating expenses and lower revenue.
Read full transcript analysis ›